SCHEMBL1332115

SCHEMBL1332115

Cn1cc(-c2n[nH]c3cc(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4Cl)ccc23)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.55
DDR2 Q16832 1/20 0.55
NTRK1 P04629 3/20 0.54
AURKB Q96GD4 8/20 0.53
FLT3 P36888 4/20 0.53
KIT P10721 3/20 0.53
AURKA O14965 3/20 0.53
AXL P30530 3/20 0.51
KDR P35968 5/20 0.49
LCK P06239 3/20 0.48
ABL1 P00519 2/20 0.48
FYN P06241 2/20 0.48
CSF1R P07333 2/20 0.48
LYN P07948 2/20 0.48
SRC P12931 2/20 0.48
FLT1 P17948 2/20 0.48
BLK P51451 2/20 0.48
MAP4K4 O95819 2/20 0.48
MET P08581 2/20 0.48
PDGFRA P16234 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331695 0.90 AURKB (0.61) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1330301 0.83 AXL (0.60) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1331716 0.82 MAPK1 (0.57) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1331849 0.81 MAPK1 (0.56) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1332041 0.80 KDR (0.69) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1331850 0.79 FGFR1 (0.64) FGFR1DDR2NTRK1AURKBAXL
SCHEMBL1330136 0.79 AXL (0.62) FGFR1DDR2AURKBAXLKDR
SCHEMBL1331406 0.79 FGFR1 (0.58) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1330486 0.79 KDR (0.62) FGFR1DDR2NTRK1AURKBFLT3
SCHEMBL1330237 0.79 FGFR1 (0.70) FGFR1DDR2NTRK1AURKBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB FGFR1 227/4885DDR2 1265/4885NTRK1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.